Fluoxetine-induced alteration of murine gut microbial community structure: evidence for a microbial endocrinology-based mechanism of action responsible for fluoxetine-induced side effects
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: Depression and major depressive disorder affect 25% of the population. First line treatment utilizing selective serotonin reuptake inhibitors (SSRIs) have met with limited success due to well-recognized negative side effects which include weight gain or loss. This inability to control unwanted side effects often result in patients stopping their antidepressant medications. The mechanisms underlying the failure of SSRIs are incompletely understood. Methods: Male CF-1 mice (5 weeks of age, N = 10 per group) were per orally administered fluoxetine (20 mg per kg body weight) or diluent daily for 29 days. During this time fecal specimens were collected at three defined time points (0, 15 and 29 days). At the conclusion of the 29-day dosing regimen, animals were subjected to two behavioral assessments. For bacterial identification of the microbiota, 16S rRNA gene sequencing was performed on 60 fecal specimens (three specimens per mouse time course, N = 20 mice) using Illumina MiSeq. Analysis of community sequence data was done using mothur and LEfSe bioinformatic software packages. Results: Daily per oral administration of fluoxetine for 29 days to male mice resulted in a significant, time dependent, alteration in microbial communities accompanying changes in body weight. The calculated species richness and diversity indicators of the murine fecal microbial communities were inconsistent and not significantly different between the groups. Among the phylotypes decreased in abundance due to fluoxetine administration were Lactobacillus johnsonii and Bacteroidales S24-7 which belong to phyla associated with regulation of body mass. The observed changes in body weight due to fluoxetine administration mimicked the dramatic shifts in weight gain/loss that has been observed in humans. Further, at the conclusion of the 29-day dosing regimen fluoxetine-dosed animals evidenced a mild anxiogenic-like behavior. Discussion: We report that the most widely used antidepressant, fluoxetine, which is an SSRI-type drug, results in the selective depletion of gut microbiota, specifically the Lactobacilli which are involved in the regulation of body weight. Concomitantly, fluoxetine administration increases the abundance of phylotypes related to dysbiosis. Since Lactobacilli have been previously shown to possess a known biogenic amine transporter that regulates the uptake of fluoxetine, it is proposed that a microbial endocrinology-based mechanistic pathway is responsible for the ability of SSRIs to selectively negatively impact beneficial microbiota. The results of this study therefore suggest that the negative clinical side effects due to fluoxetine administration may be due to alterations in gut microbiota. Further, the data also suggests that supplementation of bacterial genera directly affected by fluoxetine administration may prove useful in ameliorating some of the well-known side effects of chronic fluoxetine administration such as weight alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102999108 · Cited by 3,888 · cited 1×
“rhamnosus JB-1 (McVey Neufeld, Kay & Bienenstock, 2018) can influence behavior, while other lactobacilli cannot (Bravo et al., 2011; Vancanneyt et al., 2006).”
BackgroundExtensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905
Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671 · cited 4×
“This dosage, as previously discussed in the ‘Materials and Methods’ section, was chosen based upon a landmark study examining the dose response relationship of chronic per oral administration in three strains of mice and its ability to influence models of anxiety and depression (Dulawa et al., 2004).”
BackgroundMethodResultInfluentialLooking for a Signal in the Noise: Revisiting Obesity and the Microbiome
Sze, M. A., & Schloss, P. D. (2016) · mBio · doi:10.1128/mbio.01018-16 · Cited by 600 · cited 1×
“As such, there was no consistent change in one direction of weight gain or loss that could be correlated with the Firmicutes/Bacteroidetes ratios which has also been noted in humans (Sze & Schloss, 2016).”
BackgroundLipocalin 2 protects from inflammation and Tumorigenesis associated with gut microbiota alterations
Moschen, A. R., Gerner, R. R., Wang, J., Klepsch, V., Adolph, T. E., Reider, S. J., Hackl, H., Pfister, A., Schilling, J., Moser, P. L., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.03.007 · Cited by 375
Microbiota alteration is associated with the development of stress-induced despair behavior
Marin, I. A., Goertz, J. E., Ren, T., Rich, S. S., Onengut-Gumuscu, S., Farber, E., Wu, M., Overall, C. C., Kipnis, J., & Gaultier, A. (2017) · Scientific Reports · doi:10.1038/srep43859 · Cited by 369
Golubeva, A. V., Crampton, S., Desbonnet, L., Edge, D., O'Sullivan, O., Lomasney, K. W., Zhdanov, A. V., Crispie, F., Moloney, R. D., Borre, Y. E., et al. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.06.002 · Cited by 283 · cited 1×
“Furthermore, Anaerotruncus was increased in rats exposed to prenatal stress (Golubeva et al., 2015).”
BackgroundMcCafferty, J., Mühlbauer, M., Gharaibeh, R. Z., Arthur, J. C., Perez-Chanona, E., Sha, W., Jobin, C., & Fodor, A. A. (2013) · The ISME Journal · doi:10.1038/ismej.2013.106 · Cited by 259
Antimicrobial activity of psychotropic drugs
Munoz-Bellido, J. L., Munoz-Criado, S., & Garcı̀a-Rodrı̀guez, J. A. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(99)00154-5 · Cited by 249
Human gut symbiont roseburia hominis promotes and regulates innate immunity
Patterson, A. M., Mulder, I. E., Travis, A. J., Lan, A., Cerf-Bensussan, N., Gaboriau-Routhiau, V., Garden, K., Logan, E., Delday, M. I., Coutts, A. G. P., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01166 · Cited by 192
Chemical and pathogen-induced inflammation disrupt the murine intestinal microbiome
Borton, M. A., Sabag-Daigle, A., Wu, J., Solden, L. M., O’Banion, B. S., Daly, R. A., Wolfe, R. A., Gonzalez, J. F., Wysocki, V. H., Ahmer, B. M. M., et al. (2017) · Microbiome · doi:10.1186/s40168-017-0264-8 · Cited by 149
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84 · cited 1×
“Antidepressants, notably the selective serotonin reuptake inhibitors , otherwise referred to as SSRIs, are considered the first line of treatment for anxiety and major depressive disorder (Williams et al., 2017).”
BackgroundMcVey Neufeld, K.-A., Kay, S., & Bienenstock, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00294 · Cited by 79
Cited by
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
The gut microbiota in anxiety and depression—A systematic review
Simpson, C. A., Diaz-Arteche, C., Eliby, D., Schwartz, O. S., Simmons, J. G., & Cowan, C. S. M. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101943 · Cited by 912
Microbiota-Gut-Brain Axis: New Therapeutic Opportunities
Long-Smith, C., O'Riordan, K. J., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023628 · Cited by 419
Oliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., De Ronchi, D., Fanelli, G., & Serretti, A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110266 · Cited by 219
Focus on the essentials: tryptophan metabolism and the microbiome-gut-brain axis
Gheorghe, C. E., Martin, J. A., Manriquez, F. V., Dinan, T. G., Cryan, J. F., & Clarke, G. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.08.004 · Cited by 212
Metadata
- Authors
- Lyte, M., Daniels, K. M., & Schmitz-Esser, S.
- Venue
- PeerJ
- Publisher
- PeerJ
- Published
- 2019-01-09
- Volume
- 7
- Pages
- e6199
- ISSN
- 2167-8359 (ISSN-L)
- OpenAlex
- W2908540573
- Cited by
- 89
- References
- 13
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.